Pre-made Cofetuzumab benchmark antibody ( Whole mAb ADC, anti-PTK7 therapeutic antibody, Anti-CCK-4/CCK4 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Cofetuzumab biosimilar, Whole mAb ADC, Anti-PTK7 Antibody: Anti-CCK-4/CCK4 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cofetuzumab pelidotin (INN; development code PF-06647020) is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to auristatin-0101, an auristatin microtubule inhibitor.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-115-1mg	1mg	Inquiry
GMP-Bios-ab-115-10mg	10mg	Inquiry
GMP-Bios-ab-115-100mg	100mg	Inquiry
GMP-Bios-ab-115-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Cofetuzumab biosimilar, Whole mAb ADC, Anti-PTK7 Antibody: Anti-CCK-4/CCK4 therapeutic antibody
INN Name	Cofetuzumab
Target	PTK7
Format	Whole mAb ADC
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-I
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Stemcentrx;Indiana University;Pfizer;Stemcentrx
Conditions Approved	na
Conditions Active	Non-small cell lung cancer;Solid tumours
Conditions Discontinued	Breast cancer
Development Tech	na